nach oben

Erschienen in:

01.04.2017 | Impfungen | Fortbildung

Humane Papillomviren

Impfung birgt großes Potenzial

verfasst von: Prof. Dr. med. Ulrike Wieland

Erschienen in: Deutsche Dermatologie | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die prophylaktische HPV-Impfung ist äußerst effektiv: Sie bewirkt einen signifikanten Rückgang der zervikalen HPV-Prävalenz, von zervikalen Krebsvorstufen sowie von Kondylomen. Auch das Auftreten von Genitalwarzen und HPV-bedingten Dysplasien und Karzinomen kann nahezu eliminiert oder zumindest deutlich reduziert werden.

Karolinska_Institute. International Human Papillomavirus Reference Center - Reference Colones. Dec. 2016:http://www.hpvcenter.se/html/refclones.html

Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010;117(2 Suppl):S5–10. doi: 10.1016/j.ygyno.2010.01.024. PubMed PMID: 20304221CrossRefPubMed

Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med. 2011;53 Suppl 1:S12–21. doi: 10.1016/j.ypmed.2011.08.017. PubMed PMID: 21962466CrossRefPubMed

Weaver B, Shew M, Qadadri B, Tu W, Tong Y, Denski C, et al. Natural history of multiple human papillomavirus infections in female adolescents with prolonged follow-up. J Adolesc Health. 2011;48(5):473–80. doi: 10.1016/j.jadohealth.2010.08.003. PubMed PMID: 21501806CrossRefPubMed

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens—Part B: biological agents. Lancet Oncol. 2009;10(4):321–2. PubMed PMID: 19350698CrossRefPubMed

Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol. 2012;10(10):681–92. doi: 10.1038/nrmicro2872. PubMed PMID: 22961341CrossRefPubMed

Gooi Z, Chan JY, Fakhry C. The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. Laryngoscope. 2016;126(4):894–900. doi: 10.1002/lary.25767. PubMed PMID: 26845348CrossRefPubMed

Tinhofer I, Johrens K, Keilholz U, Kaufmann A, Lehmann A, Weichert W, et al. Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. Eur J Cancer. 2015;51(4):514–21. doi: 10.1016/j.ejca.2014.12.018. PubMed PMID: 25623438CrossRefPubMed

Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13:39. doi: 10.1186/1471-2334-13-39. PubMed PMID: 23347441; PubMed Central PMCID: PMCPMC3618302CrossRefPubMedPubMedCentral

10.

Wieland U, Kreuter A, Pfister H. Human papillomavirus and immunosuppression. Curr Probl Dermatol. 2014;45:154–65. doi: 10.1159/000357907. PubMed PMID: 24643184CrossRefPubMed

11.

Schiller JT, Müller M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol. 2015;16(5):e217–25. doi: 10.1016/S1470-2045(14)71179-9. PubMed PMID: 25943066CrossRefPubMed

12.

Lopalco PL. Spotlight on the 9-valent HPV vaccine. Drug Des Devel Ther. 2017;11:35–44. doi: 10.2147/DDDT.S91018. PubMed PMID: 28053505; PubMed Central PMCID: PMCPMC5191848CrossRefPubMed

13.

Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, Joura EA, et al. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother. 2015;11(6):1313–22. doi: 10.1080/21645515.2015.1012010. PubMed PMID: 25912208; PubMed Central PMCID: PMCPMC4514333CrossRefPubMedPubMedCentral

14.

de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56. doi: 10.1016/S1470-2045(10)70230-8. PubMed PMID: 20952254CrossRefPubMed

15.

Massad LS, Xie X, Burk RD, D’Souza G, Darragh TM, Minkoff H, et al. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women. Am J Obstet Gynecol. 2016;214(3):354 e1–6. doi: 10.1016/j.ajog.2015.09.086. PubMed PMID: 26433170; PubMed Central PMCID: PMCPMC4775397CrossRef

16.

Wieland U, Brockmeyer NH, Kreuter A. A 9-Valent HPV Vaccine in Women. N Engl J Med. 2015;372(26):2566. doi: 10.1056/NEJMc1504359#SA1. PubMed PMID: 26107059.CrossRefPubMed

17.

Brotherton JM, Ogilvie GS. Current status of human papillomavirus vaccination. Curr Opin Oncol. 2015;27(5):399–404. doi: 10.1097/CCO.0000000000000211. PubMed PMID: 26258273CrossRefPubMed

18.

Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016;144(3):449–68. doi: 10.1017/S0950268815002198. PubMed PMID: 26429676CrossRefPubMed

19.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol. 2015;16(7):775–86. doi: 10.1016/S1470-2045(15)00047-9. PubMed PMID: 26071347; PubMed Central PMCID: PMCPMC4498478CrossRefPubMedPubMedCentral

20.

Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Saf. 2013;36(6):393–412. doi: 10.1007/s40264-013-0039-5. PubMed PMID: 23637071CrossRefPubMed

21.

Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5:F123–38. doi: 10.1016/j.vaccine.2012.04.108. PubMed PMID: 23199956; PubMed Central PMCID: PMCPMC4636904CrossRefPubMedPubMedCentral

22.

Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J. 2015;34(9):983–91. doi: 10.1097/INF.0000000000000793. PubMed PMID: 26107345CrossRefPubMed

23.

Herweijer E, Sundstrom K, Ploner A, Uhnoo I, Sparen P, Arnheim-Dahlstrom L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study. Int J Cancer. 2016;138(12):2867–74. doi: 10.1002/ijc.30035. PubMed PMID: 26856527; PubMed Central PMCID: PMCPMC5069657CrossRefPubMedPubMedCentral

24.

Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Jr., Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401–11. doi: 10.1056/NEJMoa0909537. PubMed PMID: 21288094; PubMed Central PMCID: PMCPMC3495065CrossRefPubMedPubMedCentral

25.

Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Jr., Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85. doi: 10.1056/NEJMoa1010971. PubMed PMID: 22029979CrossRefPubMed

26.

Joura EA, Giuliano AR, Iversen OE, ouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23. doi: 10.1056/NEJMoa1405044. PubMed PMID: 25693011CrossRefPubMed

27.

Castellsague X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892–901. doi: 10.1016/j.vaccine.2015.06.088. PubMed PMID: 26144901CrossRefPubMed

28.

Van Damme P, Meijer CJ, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34(35):4205–12. doi: 10.1016/j.vaccine.2016.06.056. PubMed PMID: 27354258CrossRefPubMed

29.

Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, et al. Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics. 2015;136(1):e28–39. doi: 10.1542/peds.2014-3745. PubMed PMID: 26101366CrossRefPubMed

30.

Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, et al. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA. 2016. doi: 10.1001/jama.2016.17615. PubMed PMID: 27893068

31.

Schilling A, Parra MM, Gutierrez M, Restrepo J, Ucros S, Herrera T, et al. Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines. Pediatrics. 2015;136(3):e563–72. doi: 10.1542/peds.2014-4199. PubMed PMID: 26240207CrossRefPubMed

32.

Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134(3):e657–65. doi: 10.1542/peds.2013-4144. PubMed PMID: 25136050CrossRefPubMed

33.

Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147–62. doi: 10.4161/hv.29532. PubMed PMID: 25424918; PubMed Central PMCID: PMCPMC4896780CrossRefPubMedPubMedCentral

34.

Sanofi-Pasteur-MSD. Fachinformation Gardasil 9. Fachinfo-Service, Rote Liste Service GmbH. Mai 2016:1 - 9

35.

Schwarz T, Spaczynski M, Kaufmann A, Wysocki J, Galaj A, Schulze K, et al. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG. 2015;122(1):107–18. doi: 10.1111/1471-0528.13070. PubMed PMID: 25208608; PubMed Central PMCID: PMCPMC4489326CrossRefPubMed

36.

Robert-Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiologisches Bulletin. 2016;34:312

37.

Robert-Koch-Institut. Anwendung des neunvalenten Impfstoffs gegen Humane Papillomviren (HPV). Epidemiologisches Bulletin. 2016;16:137

38.

Coskuner ER, Ozkan TA, Karakose A, Dillioglugil O, Cevik I. Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study. J Sex Med. 2014;11(11):2785–91. doi: 10.1111/jsm.12670. PubMed PMID: 25124237CrossRefPubMed

39.

Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol. 2016;215(2):212 e1–e15. doi: 10.1016/j.ajog.2016.02.021. PubMed PMID: 26892991; PubMed Central PMCID: PMCPMC4967374CrossRef

40.

Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743–53. doi: 10.1001/jama.298.7.743. PubMed PMID: 17699008CrossRefPubMed

41.

Kreuter A, Wieland U. Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients. J Am Acad Dermatol. 2013;68(1):179–80. doi: 10.1016/j.jaad.2011.11.970. PubMed PMID: 23244376CrossRefPubMed

42.

Wilkin TJC, H.; Cespedes, M.; et al. ACTG A5298: A phase 3 trail of quadrivalent HPV vaccine in older HIV+ adults. Conference on Retroviruses and Opportunistic Infections (CROI). 2016;Abstract 161. http://www.croiconference.org/scientific-program/electronic-materials/croi-2016

43.

GSK. Fachinformation Cervarix. Fachinfo-Service, Rote Liste Service GmbH. Juli 2016:1 - 8

44.

Sanofi-Pasteur-MSD. Fachinformation Gardasil. Fachinfo-Service, Rote Liste Service GmbH. April 2016:1 - 10

45.

Abeck D, Folster-Holst R. Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children. Acta Derm Venereol. 2015;95(8):1017–9. doi: 10.2340/00015555-2111. PubMed PMID: 25824471CrossRefPubMed

46.

Daniel BS, Murrell DF. Complete resolution of chronic multiple verruca vulgaris treated with quadrivalent human papillomavirus vaccine. JAMA Dermatol. 2013;149(3):370–2. doi: 10.1001/jamadermatol.2013.1463. PubMed PMID: 23552967CrossRefPubMed

47.

Kreuter A, Waterboer T, Wieland U. Regression of cutaneous warts in a patient with WILD syndrome following recombinant quadrivalent human papillomavirus vaccination. Arch Dermatol. 2010;146(10):1196–7. doi: 10.1001/archdermatol.2010.290. PubMed PMID: 20956677CrossRefPubMed

48.

Silling S, Wieland U, Werner M, Pfister H, Potthoff A, Kreuter A. Resolution of novel human papillomavirus-induced warts after HPV vaccination. Emerg Infect Dis. 2014;20(1):142–5. doi: 10.3201/eid2001.130999. PubMed PMID: 24378072; PubMed Central PMCID: PMCPMC3884730CrossRefPubMedPubMedCentral

49.

Smith SP, Baxendale HE, Sterling JC. Clearance of recalcitrant warts in a patient with idiopathic immune deficiency following administration of the quadrivalent human papillomavirus vaccine. Clin Exp Dermatol. 2017. doi: 10.1111/ced.13038. PubMed PMID: 28070898

50.

Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906. doi: 10.1136/bmj.f5906. PubMed PMID: 24108159; PubMed Central PMCID: PMCPMC3805482CrossRefPubMedPubMedCentral

51.

Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine. 2013;31(43):4961–7. doi: 10.1016/j.vaccine.2013.08.024. PubMed PMID: 24001935CrossRefPubMed

52.

Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother. 2016;12(6):1406–17. doi: 10.1080/21645515.2016.1168952. PubMed PMID: 27029786; PubMed Central PMCID: PMCPMC4964727CrossRefPubMedPubMedCentral

53.

Goss MA, Lievano F, Seminack MM, Dana A. No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy. Obstet Gynecol. 2014;123 Suppl 1:93SCrossRef

54.

Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012;166(12):1140–8. doi: 10.1001/archpediatrics.2012.1451. PubMed PMID: 23027469CrossRefPubMed

55.

Lehtinen M, Eriksson T, Apter D, Hokkanen M, Natunen K, Paavonen J, et al. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial. Hum Vaccin Immunother. 2016;12(12):3177–85. doi: 10.1080/21645515.2016.1183847. PubMed PMID: 27841725; PubMed Central PMCID: PMCPMC5215585CrossRefPubMedPubMedCentral

56.

Macki M, Dabaja AA. Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials. Basic Clin Androl. 2016;26:16. doi: 10.1186/s12610-016-0042-7. PubMed PMID: 27895921; PubMed Central PMCID: PMCPMC5116857CrossRefPubMedPubMedCentral

57.

Scheller NM, Svanstrom H, Pasternak B, Arnheim-Dahlstrom L, Sundstrom K, Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313(1):54–61. doi: 10.1001/jama.2014.16946. PubMed PMID: 25562266CrossRefPubMed

58.

Gronlund O, Herweijer E, Sundstrom K, Arnheim-Dahlstrom L. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. J Intern Med. 2016;280(6):618–26. doi: 10.1111/joim.12535. PubMed PMID: 27478093CrossRefPubMed

59.

Moreira ED, Jr., Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, et al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016;138(2). doi: 10.1542/peds.2015-4387. PubMed PMID: 27422279

60.

EMA EMA. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. http://wwwemaeuropaeu. 2016;January:EMA/78882/2015

61.

Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14(10):958–66. doi: 10.1016/S1473-3099(14)70841-2. PubMed PMID: 25107680CrossRefPubMed

62.

Brotherton JM, Saville AM, May CL, Chappell G, Gertig DM. Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. Cancer Causes Control. 2015;26(6):953–4. doi: 10.1007/s10552-015-0568-6. PubMed PMID: 25804857CrossRefPubMed

63.

Benard VB, Castle PE, Jenison SA, Hunt WC, Kim JJ, Cuzick J, et al. Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era. JAMA Oncol. 2016. doi: 10.1001/jamaoncol.2016.3609. PubMed PMID: 27685805

64.

Tota JE, Struyf F, Merikukka M, Gonzalez P, Kreimer AR, Bi D, et al. Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. J Natl Cancer Inst. 2017;109(7). doi: 10.1093/jnci/djw300. PubMed PMID: 28132019

65.

Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013;8(7):e68329. doi: 10.1371/journal.pone.0068329. PubMed PMID: 23873171; PubMed Central PMCID: PMCPMC3714284CrossRefPubMedPubMedCentral

66.

Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, et al. Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. J Natl Cancer Inst. 2016;108(1). doi: 10.1093/jnci/djv302. PubMed PMID: 26467666; PubMed Central PMCID: PMCPMC4862406

67.

Grün N, Ährlund-Richter A, Franzen J, Mirzaie L, Marions L, Ramqvist T, et al. Oral human papillomavirus (HPV) prevalence in youth and cervical HPV prevalence in women attending a youth clinic in Sweden, a follow up-study 2013-2014 after gradual introduction of public HPV vaccination. Infect Dis (Lond). 2015;47(1):57–61. doi: 10.3109/00365548.2014.964764. PubMed PMID: 25378085CrossRef

68.

Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. doi: 10.1136/bmj.f2032. PubMed PMID: 23599298CrossRefPubMed

69.

Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80. doi: 10.1016/S1473-3099(14)71073-4. PubMed PMID: 25744474CrossRefPubMedPubMedCentral

70.

Hartwig S, Baldauf JJ, Dominiak-Felden G, Simondon F, Alemany L, de Sanjosé S, et al. Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Research. 2015;1:90–100CrossRef

71.

Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2016:1–14. doi: 10.1080/14737167.2016.1208087. PubMed PMID: 27366939

72.

Abramowitz L, Benabderrahmane D, Ravaud P, Walker F, Rioux C, Jestin C, et al. Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS. 2007;21(11):1457–65. doi: 10.1097/QAD.0b013e3281c61201. PubMed PMID: 17589192CrossRefPubMed

73.

Esser S, Kreuter A, Oette M, Gingelmaier A, Mosthaf F, Sautter-Bihl ML, et al. German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. J Dtsch Dermatol Ges. 2015;13(12):1302–19. doi: 10.1111/ddg.12726. PubMed PMID: 26612810CrossRefPubMed

74.

Fuchs W, Wieland U, Skaletz-Rorowski A, Brockmeyer NH, Swoboda J, Kreuter A, et al. The male ScreenING Study: prevalence of HPV-related genital and anal lesions in an urban cohort of HIV-positive men in Germany. J Eur Acad Dermatol Venereol. 2016;30(6):995–1001. doi: 10.1111/jdv.13539. PubMed PMID: 26833895CrossRefPubMed

75.

Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54(7):1026–34. doi: 10.1093/cid/cir1012. PubMed PMID: 22291097; PubMed Central PMCID: PMCPMC3297645CrossRefPubMedPubMedCentral

76.

Schobert D, Remy V, Schoeffski O. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev. 2012;2(1):19. doi: 10.1186/2191-1991-2-19. PubMed PMID: 23009387; PubMed Central PMCID: PMCPMC3575401CrossRefPubMedPubMedCentral

77.

Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. Proc Natl Acad Sci U S A. 2016;113(18):5107–12. doi: 10.1073/pnas.1515528113. PubMed PMID: 27091978; PubMed Central PMCID: PMCPMC4983834CrossRefPubMedPubMedCentral

78.

Robert-Koch-Institut. Impfquoten der Rotavirus-, Masern-, HPV-, und Influenza-Impfung in Deutschland. Epidemiologisches Bulletin. 2017;1:1–12

79.

Kim JJ, Burger EA, Sy S, Campos NG. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus. J Natl Cancer Inst. 2017;109(2). doi: 10.1093/jnci/djw216. PubMed PMID: 27754955; PubMed Central PMCID: PMCPMC5068562

80.

Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175–201. doi: 10.1093/jnci/djs491. PubMed PMID: 23297039; PubMed Central PMCID: PMCPMC3565628.CrossRefPubMedPubMedCentral

81.

Islami F, Ferlay J, Lortet-Tieulent J, Bray F, Jemal A. International trends in anal cancer incidence rates. Int J Epidemiol. 2016. doi: 10.1093/ije/dyw276. PubMed PMID: 27789668

82.

Chow EP, Read TR, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91(3):214–9. doi: 10.1136/sextrans-2014-051813. PubMed PMID: 25305210CrossRefPubMed

83.

Sächsische-Impfkommission. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen. Impfempfehlung E1 https://wwwslaekde/media/dokumente/02medien/Patienten/gesundheitsinformationen/impfen/E1_2017_Druckpdf. 2017;01.01.2017

84.

Alemany L, Cubilla A, Halec G, Kasamatsu E, Quiros B, Masferrer E, et al. Role of Human Papillomavirus in Penile Carcinomas Worldwide. Eur Urol. 2016;69(5):953–61. doi: 10.1016/j.eururo.2015.12.007. PubMed PMID: 26762611CrossRefPubMed

85.

HPV-Information-Center. Human Papillomavirus and Related Diseases Report: Germany. October 2016:www.hpvcentre.net

86.

Robert-Koch-Institut. Bericht zum Krebsgeschehen in Deutschland 2016. Nov 2016:72 - 7

87.

CDC. Genital HPV Infection - Fact Sheer. Centers for Disease Control and Prevention. Dec 2016:http://www.cdc.gov/std/hpv/stdfact-hpv.htm

Titel: Humane Papillomviren
Impfung birgt großes Potenzial
verfasst von: Prof. Dr. med. Ulrike Wieland
Publikationsdatum: 01.04.2017
Verlag: Springer Medizin
Schlagwörter: Impfungen
Humane Papillomviren
Analkarzinom
Analkarzinom
Erschienen in: Deutsche Dermatologie / Ausgabe 4/2017
Print ISSN: 2731-7692
Elektronische ISSN: 2731-7706
DOI: https://doi.org/10.1007/s15011-017-1332-x

Passend zum Thema

IPD-Fallzahlen & Pneumokokken-Impfung bei Kindern in Deutschland

Das Niveau der postpandemischen Fallzahlen für invasive Pneumokokken-Erkrankungen (IPD) ist aus Sicht des Referenz-Zentrums für Streptokokken in Aachen alarmierend [1]. Wie sich die monatlichen IPD-Fallzahlen bei Kindern und Jugendlichen von Juli 2015 bis März 2023 entwickelt haben, lesen Sie hier.

HPV-Impfung: Auch für junge Erwachsene sinnvoll und wichtig

Auch nach dem 18. Lebensjahr kann eine HPV-Impfung sinnvoll und wichtig sein. Viele gesetzliche Krankenkassen übernehmen die Kosten auch zu einem späteren Zeitpunkt noch.

Impfstoffe – Krankheiten vorbeugen, bevor sie entstehen

Seit mehr als 130 Jahren entwickelt und produziert MSD Impfstoffe für alle Altersgruppen. Hier finden Sie nützliche Informationen und Praxismaterialien rund um das Thema Impfen.

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

So ersparen Sie Patienten mit einem Ulcus cruris viel Leid

Klinische Erfahrung zeigt die ganze Heterogenität

Biosimilar mit vergleichbarer Wirksamkeit

„Germany first, America second“

Schwerpunktversorger in der Minderheit

„Fußpflege ist gefährlicher als Lasertherapie“

Passend zum Thema

IPD-Fallzahlen & Pneumokokken-Impfung bei Kindern in Deutschland

HPV-Impfung: Auch für junge Erwachsene sinnvoll und wichtig

Impfstoffe – Krankheiten vorbeugen, bevor sie entstehen